British Journal of Pharmacology

British Journal of Pharmacology (2018) **175** 1260–1278 1260

Themed Section: Spotlight on Small Molecules in Cardiovascular Diseases

REVIEW ARTICLE

Multiple targets for flecainide action: implications for cardiac arrhythmogenesis

Correspondence Christopher L-H Huang, Physiological Laboratory, University of Cambridge, Downing Street, Cambridge CB2 3EG, UK. E-mail: clh11@cam.ac.uk

Received 10 February 2017; **Revised** 27 March 2017; **Accepted** 29 March 2017

Samantha C Salvage[1,2], Karthik H Chandrasekharan[2], Kamalan Jeevaratnam[3,4], Angela F Dulhunty[5], Andrew J Thompson[6], Antony P Jackson[1] and Christopher L-H Huang[1,2]

[1]Department of Biochemistry, University of Cambridge, Cambridge, UK, [2]Physiological Laboratory, University of Cambridge, Cambridge, UK, [3]Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK, [4]School of Medicine, Perdana University – Royal College of Surgeons Ireland, Serdang, Selangor Darul Ehsan, Malaysia, [5]Muscle Research Group, Eccles Institute of Neuroscience, John Curtin School of Medical Research, Australian National University, Acton, Australia, and [6]Department of Pharmacology, University of Cambridge, Cambridge, UK

Flecainide suppresses cardiac tachyarrhythmias including paroxysmal atrial fibrillation, supraventricular tachycardia and arrhythmic long QT syndromes (LQTS), as well as the Ca^{2+}-mediated, catecholaminergic polymorphic ventricular tachycardia (CPVT). However, flecainide can also exert pro-arrhythmic effects most notably following myocardial infarction and when used to diagnose Brugada syndrome (BrS). These divergent actions result from its physiological and pharmacological actions at multiple, interacting levels of cellular organization. These were studied in murine genetic models with modified Na_v channel or intracellular ryanodine receptor (RyR2)-Ca^{2+} channel function. Flecainide accesses its transmembrane $Na_v1.5$ channel binding site during activated, open, states producing a use-dependent antagonism. Closing either activation or inactivation gates traps flecainide within the pore. An early peak I_{Na} related to activation of Na_v channels followed by rapid de-activation, drives action potential (AP) upstrokes and their propagation. This is diminished in pro-arrhythmic conditions reflecting loss of function of $Na_v1.5$ channels, such as BrS, accordingly exacerbated by flecainide challenge. Contrastingly, pro-arrhythmic effects attributed to prolonged AP recovery by abnormal late I_{NaL} following gain-of-function modifications of $Na_v1.5$ channels in LQTS3 are reduced by flecainide. Anti-arrhythmic effects of flecainide that reduce triggering in CPVT models mediated by sarcoplasmic reticular Ca^{2+} release could arise from its primary actions on Na_v channels indirectly decreasing $[Ca^{2+}]_i$ through a reduced $[Na^+]_i$ and/or direct open-state RyR2-Ca^{2+} channel antagonism. The consequent $[Ca^{2+}]_i$ alterations could also modify AP propagation velocity and therefore arrhythmic substrate through its actions on $Na_v1.5$ channel function. This is consistent with the paradoxical differences between flecainide actions upon Na^+ currents, AP conduction and arrhythmogenesis under circumstances of normal and increased RyR2 function.

LINKED ARTICLES

This article is part of a themed section on Spotlight on Small Molecules in Cardiovascular Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.8/issuetoc

Abbreviations

AP, action potential; APD, action potential duration; AV, atrioventricular; BrS, Brugada syndrome; CaM, calmodulin; CaMKII, calmodulin kinase II; CASQ, calsequestrin; CAST, Cardiac Arrhythmia Suppression Trial; CPVT, catecholaminergic polymorphic ventricular tachycardia; DAD, delayed afterdepolarization; ECG, electrocardiographic; I_{CaL}, L-type calcium current; I_{Kr}, rapidly activating delayed rectifier current; I_{Ks}, slowly activating delayed rectifier current; I_{Na}, inward sodium current; I_{NaL}, late inward sodium current; I_{to}, transient outward current; LQTS, long QT syndrome; NCX, sodium-calcium exchanger; PR, standard P to R interval on ECG recording; QRS, standard QRS interval on ECG recording; QT, standard QT interval on ECG recording; RyR, ryanodine receptor; SR, sarcoplasmic reticular; VT, ventricular tachycardia

DOI:10.1111/bph.13807

Introduction

Cardiac arrhythmias constitute an important clinical and public health problem. Pharmacological modes of action, effectiveness and specific indications of anti-arrhythmic agents are therefore of particular interest (Huang, 2017). This is particularly so when they exert contrasting, beneficial, ineffective or even harmful actions dependent upon the particular physiological or clinical circumstances under which they are applied. The class Ic anti-arrrhythmic agent **flecainide** ((*RS*)-*N*-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy) benzamide); $C_{17}H_{20}F_6N_2O_3$) (Figure 1A) was derived from explorations of 2,5-bis(2,2,2-trifluoroethoxy) benzamide compounds as pharmaceutical candidates. Early studies in intact canine hearts demonstrated that flecainide markedly increased ventricular fibrillation thresholds following supraventricular beats and ventricular premature beats and slowed ectopic atrial and ventricular pacemakers. It also prolonged atrioventricular (AV) conduction (at plasma concentrations of 0.4 to 0.7 $\mu g \cdot mL^{-1}$) and overall excitation delay (at >6.5 $\mu g \cdot mL^{-1}$) (Hodess *et al.*, 1979). Standard microelectrode techniques attributed these findings to reductions in maximal rates of rise of the action potential (AP), $(dV/dt)_{max}$, in the absence of stimulation. These became accentuated during stimulus trains with stimulus intervals <4800 ms over 20 to 50 beats in guinea pig ventricle even at normal resting potentials. Flecainide also produced negative steady-state shifts in the relationship between $(dV/dt)_{max}$ and membrane potential of possible clinical relevance in ischaemic states (Campbell and Vaughan Williams, 1983).

In common with other anti-arrhythmic agents, flecainide also affected cardiac contractile activation processes, dose-dependently decreasing peak left ventricular isovolumic pressure and peak isovolumic rate of pressure generation, $(dP/dt)_{max}$, in intact rat hearts (Hoffmeister *et al.*, 1987; Fernandes *et al.*, 2014). These findings correlated with decreased aequorin luminescence and isometric tension signals in isolated canine ventricular trabeculae and reduced L-type Ca^{2+} current, I_{CaL}, in isolated myocytes from the same ventricle (Kihara *et al.*, 1996). These findings translated to effects on peak isometric contractile force and maximal rates of force development and decline in human ventricular muscle (Lynch *et al.*, 2013). These results suggest multiple, potentially interacting, actions requiring analysis at the systems level, whose mechanisms and pharmacological implications are reviewed in this present article.

Anti-arrhythmic effects of flecainide

Initial clinical studies reported encouraging effects of flecainide on occurrences of premature ventricular or atrial contractions in arrhythmic patients while minimally altering their electrocardiographic (ECG) PR, QRS or QT intervals or producing other side effects (Somani, 1980). The compound has a high bioavailability. Its amide group has a pKa of ~9.3 (Liu *et al.*, 2003), and so, it is 99% protonated as a water soluble monovalent cation at physiological pH. Peak blood levels are reached 1 to 6 h after oral ingestion (Smith, 1985). Its plasma half-life is 12 to 27 h (Padrini *et al.*, 1993). Subsequent reports similarly confirmed that even low (100 mg twice daily) flecainide doses reduced both triggering events represented by premature ventricular contractions (Abitbol *et al.*, 1983) and substrate reflected in the appearance of ventricular tachycardia (VT) following programmed electrical stimulation, during Holter monitoring and electrophysiological testing (Somberg and Tepper, 1986). Its pharmacokinetics permitted oral administration (Anderson *et al.*, 1981; Pottage, 1983; Holmes and Heel, 1985). Orally administered flecainide also suppressed premature ventricular complexes and VT (Anderson *et al.*, 1981) and proved acceptable for long-term use (Meinertz *et al.*, 1984).



Figure 1

Chemical structures of flecainide and related pharmacological agents. (A) Flecainide and (B) propafenone are class Ic cardiotropic agents. (C) Tetracaine is a ryanodine receptor antagonist, and (D) lignocaine and (E) mexiletene are class Ib cardiotropic agents. (F) Quinidine is a class Ia cardiotropic agent.

These findings led to the use of flecainide in preventing and treating ventricular ectopic events and tachycardias, paroxysmal atrial fibrillation (Anderson *et al.*, 1989) and supraventricular tachycardia, including AV nodal re-entrant tachycardia and Wolff–Parkinson–White syndrome (Henthorn *et al.*, 1991; Pritchett *et al.*, 1991). It was also beneficial for long QT syndromes, particularly the long QT syndrome type 3 (LQTS3), associated with gain-of-function mutations in **$Na_v1.5$** channels (Shimizu and Antzelevitch, 1999). Low-dose, oral flecainide shortened corrected QT (QTc) intervals and normalized repolarization T-wave patterns in LQTS3 patients with *SCN5A*-ΔKPQ mutations (Windle *et al.*, 2001; Moss *et al.*, 2005), consistent with its application as a mutation-specific therapy for LQTS3 (Benhorin *et al.*, 2000). Flecainide was relatively free of adverse, particularly neurological and gastrointestinal, side effects at effective dose levels (Anderson *et al.*, 1981; Pottage, 1983; Holmes and Heel, 1985).

Pro-arrhythmic effects of flecainide: the CAST trial

Through its long history of clinical benefit, the use of flecainide has been shadowed by pro-arrhythmic consequences under some clinical circumstances, particularly in the presence of ischaemic or morphological changes. Ventricular tachyarrhythmias and severe bradycardia occur when its narrow therapeutic index is exceeded by frank overdose or with chronic cardiac disease. Such cases show increased PR and QRS intervals suggesting depressed conduction and signs and symptoms attributable to overt heart failure, likely to reflect acutely decreased myocardial contractility (Winkelmann and Leinberger, 1987). An early study reported that 7 of 152 patients showed pro-arrhythmic effects including VT or ventricular fibrillation over an ~22 month period, similarly associated with increased PR intervals and widened QRS complexes rather than QTc prolongation (Nathan *et al.*, 1984). Additionally, in the Cardiac Arrhythmia Suppression Trial (CAST), anti-arrhythmic therapy with encainide, flecainide or **moricizine** initially suppressed arrhythmia in 1727 of 2309 post-myocardial infarction patients with asymptomatic or mildly symptomatic ventricular arrhythmia during Holter recording. However, encainide or flecainide-treated patients showed a higher incidence (8.9%) of arrhythmic death than patients assigned to placebo (1.2%) over a 10 month follow-up (CAST Investigators, 1989; Echt *et al.*, 1991; Greenberg *et al.*, 1995). Finally, flecainide has proved pro-arrhythmic in individuals suspected of having Brugada syndrome (BrS) where it can unmask its characteristic ECG findings, a fact used in its clinical diagnosis in equivocal cases (Gasparini *et al.*, 2003; Wolpert *et al.*, 2005; Meregalli *et al.*, 2006).

Na_v channel activation and inactivation processes

These multifarious actions of flecainide under different clinical circumstances may reflect arrhythmias being multicellular phenomena. They involve *triggering* mechanisms formed by spontaneous electrophysiological events occurring independently of the normal cardiac pacing process. In addition, the presence of *arrhythmic substrate* in the form of further electrophysiological abnormalities could perpetuate this arrhythmic event. These depend upon the electrophysiological stability of cellular excitation involving the interacting properties of numerous channel types, alterations in AP conduction between myocytes and the effects of myocardial anatomy. Understanding the effects of flecainide therefore not only concerns its actions at the molecular level but also their systems-level consequences. It would then be necessary to consider interacting functional changes at the cellular, tissue and organ levels and to correlate these with the targeted clinical outcome. The following sections explore the extent to which these diverse actions of flecainide under various disease paradigms are accounted for by its actions upon multiple interacting cellular targets, of which the most prominent are the voltage-gated Na_v ion channels.

The Na_v channel function itself poses intrinsic complexities. First, it entails distinct activation and inactivation processes. Channel *activation* depends on movements of S4 α-helices predominantly in domains DI-III whose positive charges underly their voltage-sensing function (Catterall, 2012). This process drives the rapid initial, phase 0 depolarization that activates the cardiac AP as well as its *propagation* to neighbouring and previously quiescent regions. Channel *inactivation* results from similar voltage-sensitive movement of the S4 α-helix in domain DIV, which drives pore occlusion by the cytoplasmic III–IV linker (Kühn and Greeff, 1999). A further slow inactivation may involve further conformational changes in the α-subunit pore region (Ulbricht, 2005). Secondly, the resulting inward Na^+ current, I_{Na}, may include one or more current components, each with different kinetics. These might reflect either modulations in the function of individual cardiac $Na_v1.5$ channels or distinct channel subpopulations (Saint *et al.*, 1992; Saint, 2009). An early peak I_{Na} related to Na_v channel activation drives the rapid early AP upstroke, thereby generating local circuit currents underlying AP propagation, rapidly inactivating within a few milliseconds. The resulting membrane depolarization activates a variety of further ion channels.

In addition to I_{Na} inactivation, *AP recovery* initially involves activation of transient outward (**I_{to}**) currents. The initial $Na_v1.5$ channel-mediated depolarization also activates plateau Ca^{2+} currents (**I_{CaL}**) that locally elevate cytosolic [Ca^{2+}] triggering Ca^{2+} release from the sarcoplasmic reticulum (SR), mediated by the **ryanodine receptor type 2 (RyR2)**. This leads to mechanical activation, with consequences for Ca^{2+} homeostasis and possible reciprocal interactions with surface channel excitability. Finally, a variety of voltage-gated K^+ channels, carrying the delayed rectifiers **I_{Kr}** and **I_{Ks}**, and the inwardly rectifying **I_{K1}**, drives the final repolarization restoring the resting potential. This recovery is opposed by late inward Na^+ current, I_{NaL}, of magnitude ~1–2% of the peak $I_{Na,}$ (Noble and Noble, 2006; Makielski, 2016). Although I_{NaL} shows a more negative (by −20 mV) voltage dependence in its activation properties (Saint *et al.*, 1992), its channel conductance, mean open



Figure 2

Flecainide docking into the voltage-gated sodium channel crystal structure NavRh (pdbid: 4DXW). (A) Alignment of the IV-S6 region of different voltage-gated Na^+ channels, highlighting the phenylalanine residue (IV-S6-phe) that is strongly implicated in flecainide binding. (B) *In silico* docking of flecainide into NavRh locates the ligand in a hydrophobic pocket. The upper panels show NavRh as viewed from the top, and the lower panels as viewed from the side. The four colours represent the four domains that constitute the functional protein. The boxes to the right show the flecainide (pink) binding site represented as a cartoon. Note that as flecainide binds within the pore of the channel, the site has been visualized as a slice through the protein; this excludes some of the overlying helices. Hydrogen bond interactions (dashed red line) are predicted with IV-S6-phe. At Nav1.4, a cation-π interaction is seen at the same location (Ahern *et al.*, 2008). (R)-flecainide was generated *ab initio* using Chem3D Prov14.0 (CambridgeSoft, Cambridge, UK), energy minimized using the implemented MM2 force field and docked using GOLD Suite v5.3 (The Cambridge Crystallographic Data Centre, Cambridge, UK) with the GoldScore function and default settings. Amino acid sequences used in the ClustalW alignment are 4DXW and 4EKW taken directly from structures of bacterial sodium channels; r_brain II = P04775; h_Nav1.1 = NP_001189364; h_Nav1.2 = NP_001035232; h_Nav1.4 = NP_000325; h_Nav1.5 = NP_932173; hNav1.7 = ABI51981.

times and selectivity properties are otherwise identical to the remaining I_{Na} (Ju *et al.*, 1992). Increased I_{NaL} influences AP duration and the refractory period. Finally, with repolarization to the resting potential, the $Na_v1.5$ channels recover their capacity for re-excitation, resulting in absolute and relative refractory periods. These correspond to the time intervals over which the channels either cannot be re-excited whatever the stimulus intensity, or require increased stimulus amplitudes for such re-excitation.

Molecular pharmacology of flecainide

Studies of clinically occurring $Na_v1.5$ channel variants showed that mutations in the IV-S6 helix were most commonly associated with altered responses to flecainide and overlapping interactions with other, similarly cationic and hydrophobic, local anaesthetics. They thus suggested that the flecainide binding site on $Na_v1.5$ channels is close to this region (Figure 2) (Viswanathan *et al.*, 2001; Liu *et al.*, 2002, 2003; Viswanathan and Balser, 2004; Fozzard *et al.*, 2011). Other amino acid substitution studies revealed that only two IV-S6 residues affected interactions of $Na_v1.5$ channels with anaesthetics (Ragsdale *et al.*, 1994; Yarov-Yarovoy *et al.*, 2002; Hanck *et al.*, 2009). In particular, unnatural amino acid mutagenesis showed that high-affinity binding of **lignocaine** highly depended upon cation-π interactions with phenylalanine-1759; it is possible that the positive charge of flecainide could similarly interact (Figure 2A) (Ahern *et al.*, 2008). Figure 2B illustrates this region by docking flecainide into a proteobacterial homologue of the $Na_v1.5$ channel (NavRh) (Zhang *et al.*, 2012). In this docked pose, flecainide occupies a hydrophobic cavity at the interface of adjacent subunits and makes contact with the important phenylalanine in IV-S6.

In K^+ channels, including the **$K_v11.1$** channels, flecainide may have similar binding sites that also overlap with binding sites for other ligands, such as the structurally related **propafenone** (Figure 1B). Binding is again heavily influenced by interactions with a phenylalanine residue in the S6 helix (Madeja *et al.*, 2010; Melgari *et al.*, 2015). These effects appeared to be mediated by charged rather than uncharged flecainide accessing the channel from the cell interior. Studies of its effects on I_{KR} from expressed **$K_v11.1$** channels, containing a range of single site mutations, suggested that flecainide binds low in the inner channel cavity (Melgari *et al.*, 2015). These similarities suggest that flecainide binding is constrained even between receptor subtypes. Such shared sites of action are perhaps not surprising. Elsewhere, different members of the Cys-loop family of ligand-gated ion channels also share a common transmembrane binding site for anaesthetics (Forman *et al.*, 1995; Nury *et al.*, 2011).

Na_v channel antagonism by flecainide

Flecainide acts upon the activated, open, state of $Na_v1.5$ channels (Anno and Hondeghem, 1990; Nitta *et al.*, 1992; Nagatomo *et al.*, 2000) (Figure 3A), gaining access to a transmembrane binding site where it blocks the pore, and inhibits I_{Na} (Liu *et al.*, 2002, 2003) (Figure 3B). I_{Na} inhibition takes place with a low affinity (IC_{50} = 345 μM) during brief depolarizing steps. However, the affinity dramatically increases (IC_{50} = 7.4 μM) with increasing stimulation frequency as expected for use-dependent binding. This use-dependent antagonism occurs at concentrations as low as 0.5 μM and saturates at ≥50 μM flecainide (Nitta *et al.*, 1992). It is reflected in an increasing inhibition of I_{Na} (Figure 4A, left panel) and a consequent shift in the dependence of I_{Na} inhibition towards lower flecainide concentrations under conditions of increasing pulsing frequency (Figure 4A, right panel) (Penniman *et al.*, 2010). This accounts for progressive increases in AP refractory periods, decreases in $(dV/dt)_{max}$ and increases in action potential duration (APD) with increasing stimulus frequencies in hearts of a range of species (Figure 4B) (Wang *et al.*, 1990). Consistent with this, in a non-inactivating $Na_v1.5$ channel mutant, flecainide produced decays in I_{Na} with a time course suggesting a simple pore blocking mechanism (K_D = 11 μM). Once bound, flecainide reduces Na_v channel open times (Grant *et al.*, 2000). Flecainide binding to channels then inactivated by sustained depolarization does not contribute to Na_v channel inhibition (Nitta *et al.*, 1992; Nagatomo *et al.*, 2000; Liu *et al.*, 2002; Wang *et al.*, 2003). Flecainide action was not enhanced with sustained depolarization producing channel inactivation (Ramos and O'Leary, 2004).

Flecainide does not directly bind to closed or inactivated Na_v channels, but closing either the activation or the inactivation gate traps flecainide within the pore (Figure 3 C), slowing recovery of drug-bound channels at hyperpolarized voltages. Thus, flecainide slowed recovery of both rapidly inactivating (τ ~ 81 s) and non-inactivating (τ ~ 42 s) channels with hyperpolarization. The mutation of a conserved isoleucine, SCN5A-I1756C, within the pore forming region (DIV-S6), accelerated recovery of both rapidly inactivating (τ ~ 12.6 s) and non-inactivating (τ ~ 7.4 s) channels. These observations suggest that flecainide is trapped rather than tightly bound within the pore when channels are closed or inactivated (Ramos and O'Leary, 2004).

Contrasting actions of flecainide in ion channel models for arrhythmia

Experimental studies suggest that some of the contrasting effects of flecainide reflect the differing mechanisms underlying arrhythmia in the particular models under study (Figure 5). They suggest that flecainide exerts *pro-arrhythmic effects* upon arrhythmic substrate attributable to compromised AP activation and propagation resulting from a reduced peak I_{Na} correspondingly compromising AP upstroke velocities, $(dV/dt)_{max}$. This situation is likely in the BrS, whose commonest genetic accompaniment is an inherited loss-of-function in $Na_v1.5$ channels, associated with increased risks of potentially fatal ventricular arrhythmias particularly in middle aged (40–45 years) males (Brugada *et al.*, 2002). It has been modelled in isolated murine heterozygotic $Na_v1.5$ channel haplo-insufficient *Scn5a*$^{+/-}$ cardiac preparations (Papadatos *et al.*, 2002). These preparations replicated the clinically observed arrhythmic



Figure 3

Open state antagonism of the voltage-gated sodium channel by flecainide. (A) Voltage-gated Na_v channel is represented in its closed, resting state. Surface membrane depolarization detected by the S4 segment-voltage sensor drives opening of the activation gates. This switches the channel to the (B) open state for a finite ~1 ms interval permitting selective Na^+ entry. Flecainide gains access to its binding site on the cytoplasmic side of the channel pore, thereby preventing or reducing Na^+ entry into the intracellular compartment. Subsequent inactivation involving the cytoplasmic III–IV linker results in occlusion of the pore and can result in (C) trapping of flecainide in the channel. The use-dependent action of flecainide reflects its gaining access to its binding site only when the channel is in the open state. Thus, repetitive depolarizations that allow for the refractory period of the inactivated state result in higher potency.

tendencies and attributed these to compromised AP conduction particularly following extrasystolic stimuli, findings that correlate with biophysical observations of a reduced peak I_{Na} (Martin *et al.*, 2011b, 2012). Flecainide challenge also reproduced clinical observations, as it increased these ventricular arrhythmic tendencies (Stokoe *et al.*, 2007a; Martin *et al.*, 2010; Matthews *et al.*, 2013). The altered balance between inward I_{Na} and outward I_{to} mediating early AP repolarization would also be expected to increase the likelihood of pro-arrhythmic phase II re-entry phenomena (Lukas and Antzelevitch, 1996), although these would be made less likely as flecainide also increases effective refractory periods (Martin *et al.*, 2011a).

In contrast, flecainide exerts *anti-arrhythmic effects* under conditions associated with abnormal AP recovery, particularly when arising from increased I_{NaL}. The open channel antagonist nature of flecainide action on $Na_v1.5$ channels could make it particularly effective on Na_v channels showing prolonged dwell times, as with the increased I_{NaL} in LQTS3. Patch-clamp studies on the HEK293 expression



Figure 4

Rate-dependent effects of flecainide on I_{Na}, effective refractory period (ERP), V_{max} and APD_{95} in different species. (A) Left hand panel: superimposed Na^+ currents, I_{Na}, recorded from HEK293 cells expressing $hNa_v1.5$ channels before and after application of 3 and 30 μM flecainide at different pulsing rates, illustrating use-dependent antagonism. Right hand panel: average steady-state I_{Na} inhibition by flecainide at each pulsing rate expressed as a fraction of control current obtained in the absence of flecainide at that pulsing rate. IC_{50} of flecainide at each pacing rate was determined from the Hill coefficient (adapted with permission from Figure 6A and B of Penniman *et al.*, (2010)). (B) The effects of flecainide on (from left to right) ERP, maximum rate of AP depolarization (V_{max}) and action potential duration at 95% recovery (APD_{95}) with changing basic cycle lengths (BCL) in guinea pig, rabbit, dog and human cardiac action potentials. With decreasing BCL, there was an increasing effect of flecainide on prolongation of both ERP and APD_{95}, and a decreasing V_{max} (figure adapted with permission from left hand panels of Figures 2–4 of Wang *et al.*, (1990)).

system demonstrated that flecainide exerted a more marked tonic and use-dependent I_{Na} antagonism in *Scn5a*$^+$/ΔKPQ than wild-type (WT). *Scn5a*$^+$/ΔKPQ channels showed a greater use-dependent antagonism of both peak I_{Na} and I_{NaL} than WT channels. In both cases, flecainide preferentially inhibited I_{NaL} (IC_{50} ~ 19 vs. 44 μM) over peak I_{Na} (IC_{50} ~ 80 vs. 127 μM) (Nagatomo *et al.*, 2000).

In LQTS3, both AP prolongation and increased arrhythmic tendency is attributed to increased late Na^+ current I_{NaL} and a consequent persistent Na_v channel opening. This thus provides a pro-arrhythmic exemplar distinct from arrhythmia arising from deficient peak I_{Na} in BrS. Murine *Scn5a*$^+$/ΔKPQ hearts modelled this clinical arrhythmic phenotype. For example, isolated, Langendorff-perfused, *Scn5a*$^+$/ΔKPQ hearts showed increased arrhythmogenicity on programmed electrical stimulation. Their monophasic APs were prolonged, accounting for the observed increases in electrocardiographic QT intervals. Biophysical studies attributed these changes to increased I_{NaL} (Bennett *et al.*, 1995; Nuyens *et al.*, 2001; Head *et al.*, 2005). This was accompanied by increased frequencies of early afterdepolarization events that could potentially act as arrhythmic triggers (Damiano and Rosen, 1984; Wang *et al.*, 1995a; Thomas *et al.*, 2008; Belardinelli *et al.*, 2015). The latter have been attributed to elevations of $[Na^+]_i$ promoting reverse mode activity of the Na^+–Ca^{2+} exchanger (**NCX**) activity. This results in the pro-arrhythmic alterations in cellular Ca^{2+} homeostasis further discussed below (Shryock *et al.*, 2013). The ventricles also showed altered transmural APD gradients across the ventricular wall potentially providing arrhythmic substrate (January and Riddle, 1989; Sabir *et al.*, 2008; Horvath *et al.*, 2013). Both these abnormalities and their associated arrhythmic tendencies were abolished by flecainide (Stokoe *et al.*, 2007b; Sabir *et al.*, 2008). This feature reproduces the clinically established, anti-arrhythmic effects of flecainide in LQTS3 (Windle *et al.*, 2001; Moss *et al.*, 2005), further demonstrating that murine hearts can provide useful models for the human condition.

Occurrences of flecainide exerting pro- rather than anti-arrhythmic effects in LQTS3 have also been reported.



Figure 5

Feed-forward effects of flecainide attributable to its actions on $Na_v1.5$ channels. In this hypothesis, flecainide reduces peak, I_{Na}, thereby reducing AP conduction velocity, exacerbating pro-arrhythmic conditions arising from *loss* of function in $Na_v1.5$ channels, occurring in conditions such as BrS. In contrast, its reduction of late, I_{NaL}, would be anti-arrhythmic in conditions associated with *gain* of function in $Na_v1.5$ channels, increasing I_{NaL} and prolonging AP duration such as LQTS. The inhibitory effect of flecainide on $Na_v1.5$ channels also increases triggering threshold. Finally, reduced Na^+ entry resulting from reductions in I_{Na} reduces $[Na^+]_i$. This then indirectly reduces $[Ca^{2+}]_i$ through NCX action, thereby reducing incidences of RyR2-mediated SR Ca^{2+} release and its resulting DADs.

However, these were observed when LQTS3 phenotypic features were combined with abnormalities normally associated with a $Na_v1.5$ channel haplo-insufficient BrS, resulting in an *overlap syndrome* (Bezzina *et al.*, 1999). The latter has been modelled by murine *Scn5a*$^+$*/1795insD* hearts. In addition to the increased QTc intervals, bradycardia and bradycardic pauses expected from a LQTS3 phenotype, these showed increased PQ intervals and QRS durations suggesting slowed ventricular conduction. Patch-clamped ventricular myocytes correspondingly showed increased AP durations and increased I_{NaL}. The voltage dependences of activation, of steady-state rapid or slow inactivation and of recovery from inactivation were of normal $Na_v1.5$ channels. In addition, reduced peak I_{Na} and $(dV/dt)_{max}$, correlated with multi-electrode recordings in Langendorff-perfused hearts revealing slowed conduction of excitation (Remme *et al.*, 2006). Overlap features were also shown by ageing *Scn5a*$^+$/ΔKPQ (Guzadhur *et al.*, 2010; Wu *et al.*, 2012). These findings could account for reports that flecainide produced ST-segment elevation characteristic of BrS in some LQT3 patients, suggesting that this Na_v channel antagonist could paradoxically be pro-arrhythmic in LQTS3 in the presence of accompanying conduction abnormalities (Priori *et al.*, 2000). Such dual phenotypes have also been attributed to myocardial heterogeneities (Clancy and Rudy, 2002) or simultaneous shifts in the inactivation characteristics of $Na_v1.5$ channels (Grant *et al.*, 2002). They could also arise from differences in the effects of flecainide upon inactivation gating. Both *Scn5a*$^+$/1795insD and *Scn5a*$^+$/ΔKPQ channels expressed in tsA-201 cells exhibited modified inactivation gating from the closed channel state. However, flecainide antagonized I_{NaL} to different extents in the sequence WT < *Scn5a*$^+$/ΔKPQ < *Scn5a*$^+$/1795insD. *Scn5a*$^+$/1795insD channels also showed delayed recoveries from inactivation further exacerbated by flecainide (Viswanathan *et al.*, 2001).

Further complexities arise because Na_v channels do not occur as isolated molecules in the plasma membrane but instead are anchored within larger, extended multi-component complexes. Examples of such associated proteins include auxiliary **Na_v channel β subunits** (Cusdin *et al.*, 2010), cytoskeletal proteins (Jeevaratnam *et al.*, 2016; Huang, 2017) and other ion channels such as the inwardly rectifying **$K_{ir}2.1$** channels (Willis *et al.*, 2015). These proteins can influence Na_v channel gating behaviour both directly through protein–protein contacts and indirectly by affecting surface expression and trafficking (Abriel and Kass, 2005; Cusdin *et al.*, 2008; Abriel *et al.*, 2015).

Relatively little attention has been paid to how this supra-molecular channel clustering could influence flecainide pharmacology. To our knowledge, the only example where such effects on flecainide behaviour were studied is the case of the auxiliary Na_v channel β3 subunit, the product of the *Scn3b* gene (Hakim *et al.*, 2010). The β3 subunit is expressed in heart and modulates gating of $Na_v1.5$ channels (Yu *et al.*, 2005). Patch-clamped *Scn3b*$^{-/-}$ murine cardiomyocytes showed reduced I_{Na} , most likely reflecting reduced trafficking of $Na_v1.5$ channels to the surface membrane. This was combined with negative shifts in $Na_v1.5$ channel inactivation characteristics that would be expected to reduce

I_{NaL} but shorten refractory periods. The genetic variant accordingly shows arrhythmic phenotypes resembling that of the *Scn5a*$^{+/-}$ murine model (Hakim *et al.*, 2008). Indeed, several mutations in *SCN3B* are associated with inherited cardiac arrhythmias in humans (Namadurai *et al.*, 2015).

Curiously however, in *Scn3b*$^{-/-}$ hearts, flecainide produced reduced arrhythmic incidences combined with prolonged refractory periods and shortened APDs (Hakim *et al.*, 2010). This is in direct contrast to its effects in *Scn5a*$^{+/-}$ mice (see above). The reasons for this difference are unclear, but they further confirm suggestions that flecainide exerts dual pro- and anti-arrhythmic actions through effects on both conduction and refractoriness. Thus, in the case of *Scn5a*$^{+/-}$ hearts, the negative conduction velocity effects predominate in producing arrhythmia *exacerbated* by flecainide. In the case of LQTS3, refractoriness and recovery effects predominate in producing arrhythmia *reduced* by flecainide. The presence or absence of β3 subunits may differentially modify these two competing effects so that an anti-arrhythmic effect predominates.

How this might work is currently unknown and will probably require detailed structural insights into how the β3 subunit interacts and modulates the $Na_v1.5$ channel α subunit. The β3 subunit contains a single extracellular immunoglobulin domain, a single-pass transmembrane domain and an intracellular domain and interacts with $Na_v1.5$ channels through both its extracellular and intracellular domains (Namadurai *et al.*, 2015). It is striking however that neither of these two interaction sites are close to the flecainide binding site on $Na_v1.5$ channels (Figure 2B). This suggests that the β3 subunit most likely modulates the effects of flecainide on $Na_v1.5$ channels indirectly, either by affecting channel opening probability or by its known effects on oligomerization of $Na_v1.5$ channels (Namadurai *et al.*, 2014, 2015).

K$^+$ channel antagonism by flecainide

Flecainide also acts on voltage-gated K^+ channels (Figure 6). At <10 μM, it inhibited the rapid K^+ current, I_{KR}, tails that followed voltage clamp pulses to +30 mV in the HEK293 expression system. The effect was most noticeable in the steepest part of the I_{KR} (carried by $K_v11.1$ channels, hERG) activation curve reflecting a voltage-dependent inhibition consistent with a rapid open channel state I_{KR} antagonism similar to that described for I_{Na} (Paul *et al.*, 2002). Flecainide (>10 μM) also inhibits rapid transient outward (**$K_v4.2$ channels**) currents, I_{tof}, in both native cells (Slawsky and Castle, 1994) and heterologous expression systems (Rolf *et al.*, 2000), to extents increasing with channel inactivation and consistent with its higher affinity for the inactivated state of $K_v4.2$ channels (Wang *et al.*, 1995b). Finally, flecainide (~100 μM) inhibits the ultrarapid delayed rectifier (**$K_v1.5$** channels) current, I_{Kur} (Tamargo *et al.*, 2004; Herrera *et al.*, 2005).

Anti-arrhythmic effects of flecainide in CPVT

More recently, flecainide proved to exhibit potential therapeutic efficacy in the Ca^{2+}-mediated catecholaminergic



Figure 6
Flecainide actions on voltage-gated K_v channel subtypes.

polymorphic ventricular tachycardia (CPVT). CPVT is predominantly associated with genetic abnormalities involving the cardiac RyR2 SR Ca^{2+} release channel and the SR binding protein calsequestrin type 2 (CASQ2) respectively. CPVT results in aberrant RyR2-mediated SR Ca^{2+} release precipitated by adrenergic stress. The leaky RyR2-Ca^{2+} release initiates delayed afterdepolarizations (DADs) that might trigger polymorphic VT.

Initial findings that flecainide prevented ventricular arrhythmia in two patients with respective CASQ2 and RyR2 mutations in exercise stress tests suggested a mechanism involving reduced triggering activity (Watanabe *et al.*, 2009). These clinical effects were corroborated by further case reports in which flecainide was added to prior conventional **β-adrenoceptor** antagonist therapy (Biernacka and Hoffman, 2011; Pott *et al.*, 2011; Jacquemart *et al.*, 2012; Mantziari *et al.*, 2013; Wangüemert-Pérez *et al.*, 2014).

Combination therapy using a **β-adrenergic antagonist** and flecainide partially or completely suppressed ventricular arrhythmias in 76% of one *CASQ2* and 32 *RYR2* mutation carriers with intractable CPVT (Van Der Werf *et al.*, 2011). It also completely suppressed exercise-induced ventricular arrhythmia in all of 10 *CASQ2-D307H* patients who were experiencing exercise-induced events on β-blocker therapy alone or in combination with a Ca^{2+} channel antagonist. This remission was maintained in 8 of the 10 patients over an ~15 month follow-up period (Khoury *et al.*, 2013). Furthermore, addition of flecainide completely prevented ventricular arrhythmias during exercise testing and over long-term follow-up in 7 of 12 patients with *RYR2*, *CASQ2* or *KCNJ2* genotype-negative CPVT resistant to conventional β-blocker therapy (Watanabe *et al.*, 2013).

Flecainide monotherapy was pursued in patients carrying *RyR2* mutations in which one patient did not tolerate β-blockers and seven other patients were switched to flecainide monotherapy from combined therapy. Monotherapy with flecainide proved more effective or equal to β-blocker monotherapy, while combination therapy only proved more successful in two of the eight patients over an ~37 month follow-up period (Padfield *et al.*, 2016).

The paediatric CPVT phenotype is often more severe than the adult presentation (Hayashi *et al.*, 2009). Flecainide was used in 24% of patients in a retrospective paediatric (<19 years of age) cohort study of 226 CPVT patients. Treatment failure never occurred in any adherent patient receiving optimal doses of both flecainide and β-blocker. Flecainide monotherapy was used in a limited number of five patients. Results then compared well with results from β-blockers, implantable cardioverter defibrillators and left cardiac sympathetic denervation. All these cases showed suppression of exercise induced events; 78% remained asymptomatic, and there was no mortality on follow-up (Roston *et al.*, 2015). Pro-arrhythmic effects of flecainide of the kind observed in BrS have not been observed in the context of CPVT.

Nevertheless, given the underlying catecholaminergic trigger for CPVT, their efficacy and wide therapeutic window, the first line of current therapy continues to utilize β-blocker monotherapy. However, β-blockers are not well tolerated or do not have an adequate therapeutic efficacy in as many as 30% of cases. These are often the younger, healthier patients. In these situations, the addition of flecainide as a combined therapy may prove more effective. Thus, flecainide is an appealing therapeutic addition to traditional β-blocker monotherapy, particularly in patients resistant to such therapy or requiring high-dose β-blockers. Adverse side effects might then be reduced through the use of smaller doses of two as opposed to a larger dose of a single pharmacological agent. Recent reports have progressed to introduce flecainide monotherapy in particular cases, with encouraging preliminary results. Flecainide monotherapy emerges as an available and effective next step, where β-blockers are not tolerated or ineffective. However, the current data relies on limited studies. Further investigation is required to conclusively assess flecainide monotherapy as an earlier line of treatment, given its narrow therapeutic window (Priori *et al.*, 2013; Lieve *et al.*, 2016).

Indirect actions of flecainide on Ca^{2+}-mediated triggering of arrhythmia

Flecainide also acts upon Ca^{2+}-mediated arrhythmia, as exemplified by its use in the management of CPVT outlined above. This action may involve cellular-level interactions following its effects upon its primary molecular targets. Thus, two contrasting groups of observations both suggest *indirect*, feed-forward effects arising from its Na_v channel antagonism and additionally implicate such actions in increased thresholds for triggered pro-arrhythmic activity.

In the first of these, flecainide pretreatment reduced incidences of sustained VT in *RyR2*-R4496C$^{+/-}$ mice studied by ECG telemetry, following **adrenaline** and **caffeine** challenge, from 70 to 8%. In isolated intact regularly paced (1 Hz) *RyR2*-R4496C$^{+/-}$ ventricular myocytes, **isoprenaline** (1 μM) increased the amplitudes and accelerated the decays of spontaneous Ca^{2+} transients and increased SR Ca^{2+} load. Permeabilized *RyR2*-R4496C$^{+/-}$ ventricular myocytes similarly demonstrated greater spontaneous Ca^{2+} spark and wave activity than WT, particularly following isoprenaline challenge. Both these groups of Ca^{2+} release phenomena persisted with flecainide (6 μM) challenge but were abolished by tetracaine (Figure 1C). Patch-clamped *RyR2*-R4496C$^{+/-}$ myocytes showed increased incidences of DADs and triggered activity with isoprenaline challenge. Flecainide reduced the occurrences of the triggered but not the DAD activity. These findings suggest flecainide actions attributable to its primary effects on Na_v channel availability (Liu *et al.*, 2011). Secondly, flecainide (5 μM) reduced Ca^{2+} spark and wave frequency, but not amplitude, waveform or associated levels of SR Ca^{2+} loading in superfused, regularly paced healthy adult rat ventricular myocytes. However, **tetrodotoxin**, propafenone (Figure 1B) and lignocaine (Figure 1D) exerted similar actions (Sikkel *et al.*, 2013). These agents, all known to decrease I_{Na}, and correspondingly reducing $[Na^+]_i$, could thereby decrease $[Ca^{2+}]_i$, through an enhanced reverse mode action of the NCX (Bers and Ellis, 1982; Eisner *et al.*, 1984). This would decrease SR luminal $[Ca^{2+}]$ (Bers, 2002), reducing spontaneous SR Ca^{2+} release (Diaz *et al.*, 1997; Györke *et al.*, 2004; Lindegger and Niggli, 2005; Sikkel *et al.*, 2013).

Direct actions of flecainide on Ca^{2+}-mediated triggering of arrhythmia

Flecainide may also act *directly* on SR RyR2-Ca^{2+} release channels, probably through open-state block (Hilliard *et al.*, 2010), with efficacies and potencies varying with channel activity (Savio-Galimberti and Knollmann, 2015). Antagonism of open-state RyR2 channels may be specific to flecainide in contrast to the prolonged RyR2 channel closure produced by tetracaine (Huang, 1997; Hilliard *et al.*, 2010; Huang *et al.*, 2011). Flecainide would then produce optimal antagonist actions in association with the increased activity of 'leaky' CPVT as opposed to WT RyR2 channels. Lipid bilayer studies reported that flecainide antagonized WT-RyR2 channel opening with a half maximal inhibitory concentration (IC_{50}) of ~15 μM with the high luminal [Ca^{2+}] expected to produce spontaneous SR Ca^{2+} release (Watanabe *et al.*, 2009), reducing RyR2 open probabilities, particularly when the channels were in the open state (Hilliard *et al.*, 2010). The IC_{50} values for flecainide action became progressively lower as bilayer voltage became more positive in a direction that would increase cation current flow from the cytoplasmic to the luminal side of the bilayer. The latter would correspond to a direction opposite to that expected with spontaneous Ca^{2+} release (Watanabe *et al.*, 2009; Hilliard *et al.*, 2010; Mehra *et al.*, 2014). Conversely, IC_{50} values increased 1000-fold to mM levels at negative bilayer potentials that would result in a current flow from the lumen to the cytoplasm. This would correspond to a direction aligned with that expected for spontaneous Ca^{2+} release (Mehra *et al.*, 2014). Similarly in WT RyR2 channels exposed to EMD41000, consequently with high open probabilities, flecainide (10 μM) reduced cytoplasmic-to-luminal currents, but not the luminal-to-cytosolic current even at higher (50 μM) concentrations (Bannister *et al.*, 2015). The fully charged (QX-FL) and neutral (NU-FL) flecainide derivatives were less effective antagonists of cytoplasmic-to-luminal currents and similarly did not affect luminal-to-cytosolic current (Bannister *et al.*, 2016).

Nevertheless, flecainide may show multiple modes of inhibition of the RyR2 channels (Hwang *et al.*, 2011; Mehra *et al.*, 2014). Both cytoplasmic and luminal flecainide induced two modes of inhibition respectively associated with millisecond and second time-scale channel closures under conditions of near-maximal RyR2 channel activation. The latter was achieved by the presence of 100 μM cytoplasmic Ca^{2+} and 2 mM cytoplasmic ATP. Reducing cytoplasmic free [Ca^{2+}] to 100 nM, adding 1 mM free [Mg^{2+}] and increasing (cytoplasmic–luminal) membrane potential decreased the flecainide IC_{50}. Some of the differing observations may also reflect use of differing, native sheep or recombinant human, RyR2, preparations, levels of associated proteins, ionic conditions and directions of charge flow in the different reports. Finally, flecainide could potentially bind **calmodulin** or other intermediary proteins with differing effects from those resulting from its direct binding to RyR2 channels (Smith and MacQuaide, 2015).

In *Casq2*$^{-/-}$ mice, flecainide pre-administration reduced incidences of ventricular arrhythmic patterns such as bigeminy and biventricular tachycardia (Watanabe *et al.*, 2009). Flecainide treatment also reduced occurrences of SR Ca^{2+} release events and triggered activity in isoprenaline-treated *Casq2*$^{-/-}$ ventricular myocytes (Watanabe *et al.*, 2009). Permeabilized *Casq2*$^{-/-}$ ventricular myocytes demonstrated greater Ca^{2+} spark and wave activity than those from WT mice. This was inhibited by flecainide and R-propafenone with greater inhibitory potencies and efficacies in *Casq2*$^{-/-}$ compared with WT myocytes. Tetracaine contrastingly exerted similar effects in both groups. Furthermore, increasing Ca^{2+} spark and wave activity in WT myocytes by caffeine increased the potencies of both flecainide and propafenone but not of tetracaine. Other class I antiarrhythmic drugs, such as lignocaine, **mexiletine** and **quinidine** (Figure 1D–F) did not exhibit such anti-arrhythmic efficacy in CPVT models (Savio-Galimberti and Knollmann, 2015). This difference was attributed to the different extents to which these test agents antagonized RyR2-mediated SR Ca^{2+} release (Hwang *et al.*, 2011). Additionally, in both WT and *RyR2*-R4496C$^{+/-}$ murine Purkinje cells, flecainide suppressed spontaneous Ca^{2+} release events as effectively as did tetracaine (Kang *et al.*, 2010).

The scheme in Figure 5 summarizes the above feed-forward effects of flecainide ultimately arising from its actions on $Na_v1.5$ channels. Its action in reducing peak, I_{Na}, would result in a reduction of action potential (AP) conduction velocity. This would exacerbate arrhythmia in BrS as the phenotype in this variant is attributable to a loss of function in $Na_v1.5$ channels. In contrast, its actions in reducing late, I_{NaL}, would reduce arrhythmia in LQTS3 as this phenotype results from a gain of function in $Na_v1.5$ channels which prolongs AP duration. Inhibition of $Na_v1.5$ channels also increases triggering threshold. Finally, a reduced Na^+ entry resulting from reductions in I_{Na} reduces $[Na^+]_i$. This then indirectly reduces $[Ca^{2+}]_i$ through modifying NCX activity, in turn leading to a reduction of RyR2-mediated SR Ca^{2+} release and the incidence of DADs.

Paradoxical effects of flecainide on arrhythmic substrate produced by RyR2-mediated Ca^{2+} release

A final group of experiments suggested that these flecainide actions on RyR2-Ca^{2+} release channels, particularly those with genetic modifications related to CPVT, might further reciprocally modify Na_v channel function and the associated AP conduction velocity, with potential implications for arrhythmic substrate. Increased $[Ca^{2+}]_i$ within the physiological range produced concentration-dependent decreases in I_{Na} in rat ventricular cardiomyocytes (Casini *et al.*, 2009). This could reflect direct Ca^{2+} actions at an EF hand motif in the C-terminal region of $Na_v1.5$ channels (Wingo *et al.*, 2004). In addition, indirect actions of Ca^{2+} binding may involve an IQ domain binding site for **Ca^{2+}-calmodulin (Ca^{2+}/CaM)**. The Nav1.5 channels also contain phosphorylatable sites ($Ser^{516,\ 571}$, and Thr^{594}) within its DI-II linker. These are targeted by **CaM kinase II (CaMKII)** following Ca^{2+} binding to the EF hand motifs of calmodulin (CaM) or CaMKII. All these mechanisms positively shift the voltage dependence of Na_v current inactivation (Wingo *et al.*, 2004; Ashpole *et al.*, 2012)

and may also enhance slow Na^+ current inactivation (Tan *et al.*, 2002).

RyR2-P2328S mice demonstrated isoprenaline-induced arrhythmic episodes resembling CPVT in ECG studies (Zhang *et al.*, 2013). Their intact isolated Langendorff-perfused hearts showed pro-arrhythmic atrial and ventricular triggering and arrhythmic events associated with altered Ca^{2+} homeostasis during monophasic action potential recordings (Goddard *et al.*, 2008; King *et al.*, 2013b; Zhang *et al.*, 2013). In addition, they showed arrhythmic substrate resulting from delayed AP conduction. Atrial multi-electrode array, and ventricular micro-electrode recordings following isoprenaline challenge, showed pro-arrhythmic reductions in conduction velocity compared with WT. Intracellular microelectrode AP recordings showed correspondingly reduced maximum rates of depolarization $(dV/dt)_{max}$ (King *et al.*, 2013b; Zhang *et al.*, 2013). These changes could be attributed to (a) chronically down-regulated expression of $Na_v1.5$ channels, demonstrated in *RyR2*-P2328S ventricles (Ning *et al.*, 2016), and (b) acute actions of increased $[Ca^{2+}]_i$ upon $Na_v1.5$ channel function. Loose-patch clamp recordings demonstrated reduced peak I_{Na} in whole isolated *RyR2*-P2328S compared with WT atria to extents comparable with those reported in Nav1.5 channel-haploinsufficent *Scn5a*$^{+/-}$ hearts (King *et al.*, 2013a; Salvage *et al.*, 2015) (Figure 6A, left traces). These conduction abnormalities could not be attributed to either fibrotic change or altered connexin expression. The I_{Na} reductions were acutely replicated in WT atria with increased $[Ca^{2+}]_i$ produced by elevated extracellular $[Ca^{2+}]$, or challenge by caffeine or **cyclopiazonic acid** (King *et al.*, 2013a).

Flecainide (1 μM) modified arrhythmic tendency and conduction velocity in *RyR2*-P2328S hearts, in directions that paradoxically contrasted with its corresponding effects upon either WT and *Scn5a*$^{+/-}$ hearts. It exerted pro-arrhythmic atrial and ventricular effects in *Scn5a*$^{+/-}$ and some WT hearts, although it produced consistently anti-arrhythmic effects in *RyR2*-P2328S atria (Salvage *et al.*, 2015). Multi-electrode recording array studies demonstrated marked conduction slowing in *RyR2*-P2328S compared with WT atria. Flecainide reduced conduction velocity and indicators of AP upstroke velocity in WT hearts but did not do so in *RyR2*-P2328S hearts (Figure 7B, left panel). *RyR2*-P2328S atria similarly showed a reduced peak I_{Na} compared with WT (Figure 7A, left panel). However, whereas 1 μM flecainide reduced peak I_{Na} in WT atria, it rescued the previously reduced peak I_{Na} in *RyR2*-P2328S atria to magnitudes indistinguishable from untreated WT (Figure 7A, centre panels) while further increases to 5 μM flecainide inhibited I_{Na} in common with effects on WT (Figure 7A, right panels). Effective refractory periods were similar in untreated *RyR2*-P2328S and WT atria but were increased in flecainide-treated *RyR2*-P2328S (Figure 7B, centre panel). As a result, flecainide shortened AP wavelength as computed from the product of conduction



Figure 7

Paradoxical actions of flecainide on Na^+ current (I_{Na}), conduction velocity, refractory period and AP wavelength in homozygotic RyR2-P2328S (RyR2$^{s/s}$) hearts. (A) Loose patch clamp measurements of Na^+ current, I_{Na}, in isolated atrial preparations from WT (top row) and *RyR2*$^{S/S}$ murine hearts (bottom row) respectively demonstrate contrasting decreases and increases in peak I_{Na} with 1 μM flecainide treatment. Increasing flecainide concentration to 5 μM resulted in a reduced I_{Na} in both *RyR2*$^{S/S}$ and WT. (B) Left panel: flecainide reduced conduction velocity in the WT while conserving conduction velocity in *RyR2*$^{S/S}$ atria. Centre panel: flecainide increased atrial effective refractory periods in both WT and *RyR2*$^{S/S}$ but did so more markedly in the *RyR2*$^{S/S}$. Right panel: The product of conduction velocity and refractory period, wavelength (λ), was shorter in *RyR2*$^{s/s}$ atria than in those from WT mice. However, flecainide shortened λ in WT but increased λ in RyR2$^{s/s}$ atria (figure adapted with permission from Figure 3(a) and (b) and Figure 7 (a)–(c) of Salvage *et al.*, (2015)).



Figure 8

Feed-backward effects of flecainide on arrhythmic substrate attributable to its possible actions on RyR2-Ca^{2+} release channels. A model invoking *RyR2*-P2328S channels as a primary pharmacological target for flecainide, in addition to $Na_v1.5$ channels, may account for its effect in diminishing arrhythmic substrate. Increased RyR2-mediated SR Ca^{2+} leak, associated with *RyR2*-P2328S, down-regulates Na_v channel expression or function, compromising AP conduction and potentially producing arrhythmic substrate. Reduction of the RyR2-mediated SR-Ca^{2+} leak by flecainide rescues the compromised function of $Na_v1.5$ channels, restoring I_{Na} and thereby AP conduction and reduces arrhythmic substrate.

velocity and refractory period in WT in a direction towards increased arrhythmic substrate. In contrast, flecainide increased AP wavelength in *RyR2*-P2328S hearts consistent with its observed anti-arrhythmic effects (Figure 7B, right panel) (Salvage *et al.*, 2015).

Figure 8 summarizes these effects of flecainide upon arrhythmic substrate in terms of a hypothesis invoking *RyR2*-P2328S as a primary pharmacological target in addition to $Na_v1.5$ channels. It represents an increased RyR2-mediated SR Ca^{2+} leak associated with the *RyR2*-P2328S variant as exerting down-regulatory effects upon Na_v channel expression or function, thereby compromising AP conduction and potentially producing arrhythmic substrate. Flecainide is suggested to reduce the RyR2-mediated SR-Ca^{2+} leak. This would drive a feedback rescue of the compromised function of $Na_v1.5$ channels, restoring I_{Na} and thereby rescuing AP conduction. This would account for a net reduction in the arrhythmic substrate associated with the *RyR2*-P2328S mutation. These findings would be consistent with dual $Na_v1.5$ and RyR2-Ca^{2+} channel blocking effects of flecainide and propafenone (Figure 1A, B), in contrast to selective effects of tetracaine (Figure 1C), and lignocaine and mexiletine (Figure 1D,C) on RyR2 and $Na_v1.5$ channels respectively, in turn consistent with patterns represented by their comparative chemical structures.

Summary and conclusions

The class Ic anti-arrhythmic agent flecainide shows both pro- and anti-arrhythmic actions depending on clinical and experimental circumstances. Flecainide therapy had initially been introduced to suppress cardiac tachyarrhythmias including paroxysmal atrial fibrillation, supraventricular tachycardia and arrhythmic LQTS. It subsequently proved useful in the management of Ca^{2+}-mediated arrhythmias exemplified by CPVT. However, the CAST trial reported its pro-arrhythmic effects following myocardial infarction. In addition, pro-arrhythmic effects of flecainide have been used in diagnostic tests for BrS.

These divergent actions may reflect physiological and pharmacological actions of flecainide at multiple, interacting levels of cellular organization. There are also complexities in the interactions of flecainide with its primary target, the $Na_v1.5$ channels, as well as other possible cellular targets, in particular the RyR2-Ca^{2+} release channels. Nevertheless, flecainide appears to act specifically through accessing a cytoplasmic binding site on $Na_v1.5$ channels in their activated, open state. This results in a use-dependent antagonism. It also acts on other, K_v and RyR2-Ca^{2+} release channels, but the resulting antagonism appears similarly to involve open channel block. Closing either the activation or the inactivation gates in the $Na_v1.5$ channel traps flecainide within its pore. Na_v channel function itself involves an activation, which triggers the action potential upstroke and inactivation that influences both recovery from excitation and the refractory period. An early peak I_{Na} related to Na_v channel *activation* followed by rapid de-activation drives AP upstrokes and *propagation*. Peak I_{Na} is diminished in pro-arrhythmic conditions reflecting *loss* of function in $Na_v1.5$ channels in experimental genetic exemplars for BrS. Experimental data

confirms predictions that these conditions would be *exacerbated* by the inhibition of $Na_v1.5$ channels, following flecainide challenge. In contrast, the experimental data demonstrate that pro-arrhythmic phenotype effects attributed to abnormalities in AP *recovery,* due to increased I_{NaL} following the *gain-of-function* modifications in $Na_v1.5$ channels, in LQTS3 are *reduced* by flecainide.

Anti-arrhythmic effects of flecainide on Ca^{2+}-mediated arrhythmia in experimental CPVT models could arise from its primary Na_v channel antagonism. Through NCX activity, the resulting reduced $[Na^+]_i$ would *indirectly* decrease $[Ca^{2+}]_i$. Alternatively, a *direct* open-state RyR2-Ca^{2+} channel antagonism would also reduce SR Ca^{2+} release. In both cases, the consequently reduced $[Ca^{2+}]_i$ would decrease the likelihood of NCX-mediated DADs that could trigger arrhythmia. Such alterations in $[Ca^{2+}]_i$ could also reduce the inhibitory effects of $[Ca^{2+}]_i$ on Na_v channel function and their associated effects on AP propagation velocity and arrhythmic *substrate*. Thus, experimental studies confirm predictions of paradoxical differences between flecainide actions upon Na_v channel function, AP conduction and arrhythmia in the *RyR2*-P2328S model that contrast with its effects under circumstances of normal WT RyR2 function.

The apparently complex actions of flecainide upon cardiac arrhythmias are thus clarified by a systems analysis of actions upon different membrane proteins and their interaction with cellular Na^+ and Ca^{2+} homeostasis, using experimental models for particular arrhythmic disease states. They also lead to expectations that flecainide action would be particularly effective in conditions associated with increased channel activity. At all events, clinical use of flecainide would require physiological assessment of the underlying cause of the arrhythmia.

Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan *et al.*, 2016), and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander *et al.*, 2015a,b,c,d).

Acknowledgements

S.C.S. and A.P.J. are funded by the British Heart Foundation (PG/14/79/31102). K.J. is funded by the Fundamental Research Grant Scheme (FRGS/2/2014/SKK01/PERDANA/02/1), Ministry of Education, Malaysia and the Research Support Fund, Faculty of Health and Medical Science, University of Surrey. A.F.D. is funded by the National Health and Medical Research Council (NHMRC) of Australia (APP1126201). A.J.T. is funded by the British Heart Foundation (PG/13/39/3029). C.L.H.H. is funded by the Medical Research Council (MR/M001288/1), Wellcome Trust (105727/Z/14/Z), British Heart Foundation (PG/14/79/31102), the McVeigh Benefaction and SADS UK.

Conflict of interest

The authors declare no conflicts of interest.

References

Abitbol H, Califano JE, Abate C, Beilis P, Castellanos H (1983). Use of flecainide acetate in the treatment of premature ventricular contractions. Am Heart J 105: 227–230.

Abriel H, Kass RS (2005). Regulation of the voltage-gated cardiac sodium channel Nav1.5 by interacting proteins. Trends Cardiovasc Med 15: 35–40.

Abriel H, Rougier JS, Jalife J (2015). Ion channel macromolecular complexes in cardiomyocytes: roles in sudden cardiac death. Circ Res 116: 1971–1988.

Ahern C, Eastwood A, Dougherty D, Horn R (2008). Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ Res 102: 86–94.

Alexander SPH, Catterall WA, Kelly E, Marrion N, Peters JA, Benson HE *et al.* (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels. Br J Pharmacol 172: 5904–5941.

Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E *et al.* (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110–6202.

Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE *et al.* (2015c). The concise guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.

Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE *et al.* (2015d). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.

Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK *et al.* (1989). Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 80: 1557–1570.

Anderson JL, Stewart JR, Perry BA, Van Hamersveld DD, Johnson TA, Conard GJ *et al.* (1981). Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med 305: 473–477.

Anno T, Hondeghem LM (1990). Interactions of flecainide with guinea pig cardiac sodium channels. Importance of activation unblocking to the voltage dependence of recovery. Circ Res 66: 789–803.

Ashpole NM, Herren AW, Ginsburg KS, Brogan JD, Johnson DE, Cummins TR *et al.* (2012). $Ca2^+$/calmodulin-dependent protein kinase II (CaMKII) regulates cardiac sodium channel Nav1.5 gating by multiple phosphorylation sites. J Biol Chem 287: 19856–19869.

Bannister ML, Alvarez-Laviada A, Thomas NL, Mason SA, Coleman S, du Plessis CL *et al.* (2016). Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor. Br J Pharmacol 173: 2446–2459.

Bannister ML, Thomas NL, Sikkel MB, Mukherjee S, Maxwell C, MacLeod KT *et al.* (2015). The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2. Circ Res 116: 1324–1335.

Belardinelli L, Giles WR, Rajamani S, Karagueuzian HS, Shryock JC (2015). Cardiac late $Na(^+)$ current: proarrhythmic effects, roles in long

QT syndromes, and pathological relationship to CaMKII and oxidative stress. Heart Rhythm 12: 440–448.

Benhorin J, Taub R, Goldmit M, Kerem B, Kass RS, Windman I *et al.* (2000). Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation 101: 1698–1706.

Bennett PB, Yazawa K, Makita N, George AL (1995). Molecular mechanism for an inherited cardiac arrhythmia. Nature 376: 683–685.

Bers DM (2002). Cardiac excitation-contraction coupling. Nature 415: 198–205.

Bers DM, Ellis D (1982). Intracellular calcium and sodium activity in sheep heart Purkinje fibres - Effect of changes of external sodium and intracellular pH. Pflügers Arch Eur J Physiol 393: 171–178.

Bezzina C, Veldkamp MW, van Den Berg MP, Postma AV, Rook MB, Viersma JW*et al.* (1999). A single Na^+ channel mutation causing both long-QT and Brugada syndromes. Circ Res 85: 1206–1213.

Biernacka E, Hoffman P (2011). Efficacy of flecainide in a patient with catecholaminergic polymorphic ventricular tachycardia. Europace 13: 129–130.

Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P (2002). Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 105: 73–78.

Campbell TJ, Vaughan Williams EM (1983). Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide. Cardiovasc Res 17: 251–258.

Casini S, Verkerk AO, van Borren MMGJ, van Ginneken ACG, Veldkamp MW, de Bakker JMT*et al.* (2009). Intracellular calcium modulation of voltage-gated sodium channels in ventricular myocytes. Cardiovasc Res 81: 72–81.

CAST Investigators (1989). Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406–412.

Catterall WA (2012). Voltage-gated sodium channels at sixty: structure, function and pathophysiology. J Physiol 590: 2577–2589.

Clancy CE, Rudy Y (2002). Na^+ channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation 105: 1208–1213.

Cusdin FS, Clare JJ, Jackson AP (2008). Trafficking and cellular distribution of voltage-gated sodium channels. Traffic 9: 17–26.

Cusdin FS, Nietlispach D, Maman J, Dale TJ, Powell AJ, Clare JJ *et al.* (2010). The sodium channel {beta}3-subunit induces multiphasic gating in NaV1.3 and affects fast inactivation via distinct intracellular regions. J Biol Chem 285: 33404–33412.

Damiano BP, Rosen MR (1984). Effects of pacing on triggered activity induced by early afterdepolarizations. Circulation 69: 1013–1025.

Diaz ME, Trafford AW, O'Neill SC, Eisner DA (1997). Measurement of sarcoplasmic reticulum Ca^{2+} content and sarcolemmal Ca^{2+} fluxes in isolated rat ventricular myocytes during spontaneous Ca^{2+} release. J Physiol 501: 3–16.

Echt DS, Liebson PR, Mitchell LB, Peters RW, Obiasmanno D, Barker AH *et al.* (1991). Mortality and morbidity in patients receiving encainide, flecainide, or placebo – the Cardiac-Arrhythmia Suppression Trial. N Engl J Med 324: 781–788.

Eisner DA, Lederer WJ, Vaughan-Jones RD (1984). The quantitative relationship between twitch tension and intracellular sodium activity in sheep cardiac Purkinje fibres. J Physiol 355: 251–266.

Fernandes S, Hoyer K, Liu G, Wang W-Q, Dhalla AK, Belardinelli L *et al.* (2014). Selective inhibition of the late sodium current has no adverse effect on electrophysiological or contractile function of the normal heart. J Cardiovasc Pharmacol 63: 512–519.

Forman S, Miller K, Yellen G (1995). A discrete site for general anesthetics on a postsynaptic receptor. Mol Pharmacol 48: 574–581.

Fozzard H, Sheets M, Hanck D (2011). The sodium channel as a target for local anesthetic drugs. Front Pharmacol 2: 68.

Gasparini M, Priori SG, Mantica M, Napolitano C, Galimberti P, Ceriotti C *et al.* (2003). Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol 26: 338–341.

Goddard CA, Ghais NS, Zhang Y, Williams AJ, Colledge WH, Grace AA *et al.* (2008). Physiological consequences of the P2328S mutation in the ryanodine receptor (RyR2) gene in genetically modified murine hearts. Acta Physiol 194: 123–140.

Grant AO, Chandra R, Keller C, Carboni M, Starmer CF (2000). Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells. Biophys J 79: 3019–3035.

Grant AO, Carboni MP, Neplioueva V, Frank Starmer C, Memmi M, Napolitano C *et al.* (2002). Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. J Clin Invest 110: 1201–1209.

Greenberg HM, Dwyer EM, Hochman JS, Steinberg JS, Echt DS, Peters RW (1995). Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. Br Heart J 74: 631–635.

Guzadhur L, Pearcey SM, Duehmke RM, Jeevaratnam K, Hohmann AF, Zhang Y *et al.* (2010). Atrial arrhythmogenicity in aged $Scn5a^+$/DeltaKPQ mice modeling long QT type 3 syndrome and its relationship to Na^+ channel expression and cardiac conduction. Pflugers Arch 460: 593–601.

Györke I, Hester N, Jones LR, Györke S (2004). The role of calsequestrin, triadin, and junctin in conferring cardiac ryanodine receptor responsiveness to luminal calcium. Biophys J 86: 2121–2128.

Hakim P, Gurung IS, Pedersen TH, Thresher R, Brice N, Lawrence J *et al.* (2008). Scn3b knockout mice exhibit abnormal ventricular electrophysiological properties. Prog Biophys Mol Biol 98: 251–266.

Hakim P, Thresher R, Grace AA, Huang CL-H (2010). Effects of flecainide and quinidine on action potential and ventricular arrhythmogenic properties in Scn3b knockout mice. Clin Exp Pharmacol Physiol 37: 782–789.

Hanck DA, Nikitina E, McNulty MM, Fozzard HA, Lipkind GM, Sheets MF (2009). Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity. Circ Res 105: 492–499.

Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM *et al.* (2009). Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 119: 2426–2434.

Head CE, Balasubramaniam R, Thomas G, Goddard CA, Lei M, Colledge WH *et al.* (2005). Paced electrogram fractionation analysis of arrhythmogenic tendency in deltaKPQ Scn5a mice. J Cardiovasc Electrophysiol 16: 1329–1340.

Henthorn RW, Waldo AL, Anderson JL, Gilbert EM, Alpert BL, Bhandari AK *et al.* (1991). Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Circulation 83: 119–125.

Herrera D, Mamarbachi A, Simoes M, Parent L, Sauvé R, Wang Z *et al.* (2005). A single residue in the S6 transmembrane domain governs the differential flecainide sensitivity of voltage-gated potassium channels. Mol Pharmacol 68: 305–316.

Hilliard FA, Steele DS, Laver D, Yang Z, Marchand SJL, Chopra N *et al.* (2010). Flecainide inhibits arrhythmogenic $Ca2^+$ waves by open state block of ryanodine receptor $Ca2^+$ release channels and reduction of $Ca2^+$ spark mass. J Mol Cell Cardiol 48: 293–301.

Hodess A, Follansbee W, Spear J, Moore E (1979). Electrophysiological effects of a new antiarrhythmic agent, flecainide, on the intact canine heart. J Cardiovasc Pharmacol 1: 427–439.

Hoffmeister HM, Hepp A, Seipel L (1987). Negative inotropic effect of class-I-antiarrhythmic drugs: comparison of flecainide with disopyramide and quinidine. Eur Heart J 8: 1126–1132.

Holmes B, Heel RC (1985). Flecainide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 29: 1–33.

Horvath B, Banyasz T, Jian Z, Hegyi B, Kistamas K, Nanasi PP *et al.* (2013). Dynamics of the late Na^+ current during cardiac action potential and its contribution to afterdepolarizations. J Mol Cell Cardiol 64: 59–68.

Huang C (2017). Murine electrophysiological models of cardiac arrhythmogenesis. Physiol Rev 97: 283–409.

Huang CL-H (1997). Dual actions of tetracaine on intramembrane charge in amphibian striated muscle. J Physiol 501: 589–606.

Huang CL-H, Pedersen TH, Fraser JA (2011). Reciprocal dihydropyridine and ryanodine receptor interactions in skeletal muscle activation. J Muscle Res Cell Motil 32: 171–202.

Hwang HS, Hasdemir C, Laver D, Mehra D, Turhan K, Faggioni M *et al.* (2011). Inhibition of cardiac $Ca2^+$ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 4: 128–135.

Jacquemart C, Ould Abderrahmane F, Massin MM (2012). Effects of flecainide therapy on inappropriate shocks and arrhythmias in catecholaminergic polymorphic ventricular tachycardia. J Electrocardiol 45: 736–738.

January CT, Riddle JM (1989). Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca^{2+} current. Circ Res 64: 977–990.

Jeevaratnam K, Guzadhur L, Goh Y, Grace A, Huang CL-H (2016). Sodium channel haploinsufficiency and structural change in ventricular arrhythmogenesis. Acta Physiol 216: 186–202.

Ju YK, Saint DA, Gage PW (1992). Effects of lignocaine and quinidine on the persistent sodium current in rat ventricular myocytes. Br J Pharmacol 107: 311–316.

Kang G, Giovannone SF, Liu N, Liu F-Y, Zhang J, Priori SG *et al.* (2010). Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy. Circ Res 107: 512–519.

Khoury A, Marai I, Suleiman M, Blich M, Lorber A, Gepstein L *et al.* (2013). Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 10: 1671–1675.

Kihara Y, Inoko M, Hatakeyama N, Momose Y, Sasayama S (1996). Mechanisms of negative inotropic effects of class Ic antiarrhythmic agents: comparative study of the effects of flecainide and pilsicainide on intracellular calcium handling in dog ventricular myocardium. J Cardiovasc Pharmacol 27: 42–51.

King JH, Wickramarachchi C, Kua K, Du Y, Jeevaratnam K, Matthews HR *et al.* (2013a). Loss of Nav1.5 expression and function in murine atria containing the RyR2-P2328S gain-of-function mutation. Cardiovasc Res 99: 751–759.

King JH, Zhang Y, Lei M, Grace AA, Huang CL-H, Fraser JA (2013b). Atrial arrhythmia, triggering events and conduction abnormalities in isolated murine RyR2-P2328S hearts. Acta Physiol 207: 308–323.

Kühn FJ, Greeff NG (1999). Movement of voltage sensor S4 in domain 4 is tightly coupled to sodium channel fast inactivation and gating charge immobilization. J Gen Physiol 114: 167–183.

Lieve K, Wilde A, van der Werf C (2016). The role of flecainide in the management of catecholaminergic polymorphic ventricular tachycardia. Arrhythm Electrophysiol Rev 5: 45–49.

Lindegger N, Niggli E (2005). Paradoxical SR Ca^{2+} release in guinea-pig cardiac myocytes after beta-adrenergic stimulation revealed by two-photon photolysis of caged Ca^{2+}. J Physiol 565: 801–813.

Liu H, Atkins J, Kass RS (2003). Common molecular determinants of flecainide and lidocaine block of heart Na^+ channels: evidence from experiments with neutral and quaternary flecainide analogues. J Gen Physiol 121: 199–214.

Liu H, Tateyama M, Clancy CE, Abriel H, Kass RS (2002). Channel openings are necessary but not sufficient for use-dependent block of cardiac Na^+ channels by flecainide: evidence from the analysis of disease-linked mutations. J Gen Physiol 120: 39–51.

Liu N, Denegri M, Ruan Y, Avelino-Cruz JE, Perissi A, Negri S *et al.* (2011). Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Circ Res 109: 291–295.

Lukas A, Antzelevitch C (1996). Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia. Cardiovasc Res 32: 593–603.

Lynch JJ, Regan CP, Beatch GN, Gleim GW, Morabito CJ (2013). Comparison of the intrinsic vasorelaxant and inotropic effects of the antiarrhythmic agents vernakalant and flecainide in human isolated vascular and cardiac tissues. J Cardiovasc Pharmacol 61: 226–232.

Madeja M, Steffen W, Mesic I, Garic B, Zhorov BS (2010). Overlapping binding sites of structurally different antiarrhythmics flecainide and propafenone in the subunit interface of potassium channel Kv2.1. J Biol Chem 285: 33898–33905.

Makielski JC (2016). Late sodium current: a mechanism for angina, heart failure, and arrhythmia. Trends Cardiovasc Med 26: 115–122.

Mantziari L, Vassilikos V, Anastasakis A, Kotsaka X, Paraskevaidis S, Styliadis IH *et al.* (2013). A de novo novel cardiac ryanodine mutation (Ser4155Tyr) associated with catecholaminergic polymorphic ventricular tachycardia. Ann Noninvasive Electrocardiol 18: 571–576.

Martin CA, Grace AA, Huang CL-H (2011a). Refractory dispersion promotes conduction disturbance and arrhythmias in a $Scn5a^{+/-}$ mouse model. Pflugers Arch 462: 495–504.

Martin CA, Guzadhur L, Grace AA, Lei M, Huang CL-H (2011b). Mapping of reentrant spontaneous polymorphic ventricular tachycardia in a $Scn5a^{+/-}$ mouse model. Am J Physiol Heart Circ Physiol 300: H1853–H1862.

Martin CA, Siedlecka U, Kemmerich K, Lawrence J, Cartledge J, Guzadhur L *et al.* (2012). Reduced Na^+ and higher K^+ channel expression and function contribute to right ventricular origin of arrhythmias in $Scn5a^{+/-}$ mice. Open Biol 2: 120072.

Martin CA, Zhang Y, Grace AA, Huang CL-H (2010). Increased right ventricular repolarization gradients promote arrhythmogenesis in a murine model of Brugada syndrome. J Cardiovasc Electrophysiol 21: 1153–1159.

Matthews GDK, Guzadhur L, Sabir IN, Grace AA, Huang CL-H (2013). Action potential wavelength restitution predicts alternans and arrhythmia in murine $Scn5a^{+/-}$ hearts. J Physiol 591: 4167–4188.

Mehra D, Imtiaz MS, van Helden DF, Knollmann BC, Laver DR (2014). Multiple modes of ryanodine receptor 2 inhibition by flecainide. Mol Pharmacol 86: 696–706.

Meinertz T, Zehender MK, Geibel A, Treese N, Hofmann T, Kasper W *et al.* (1984). Long-term antiarrhythmic therapy with flecainide. Am J Cardiol 54: 91–96.

Melgari D, Zhang Y, Harchi AE, Dempsey CE, Hancox JC (2015). Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide. J Mol Cell Cardiol 86: 42–53.

Meregalli PG, Ruijter JM, Hofman N, Bezzina CR, Wilde AAM, Tan HL (2006). Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. J Cardiovasc Electrophysiol 17: 857–864.

Moss AJ, Windle JR, Hall WJ, Zareba W, Robinson JL, McNitt S *et al.* (2005). Safety and efficacy of flecainide in subjects with long QT-3 syndrome (ΔKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol 10: 59–66.

Nagatomo T, January CT, Makielski JC (2000). Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide. Mol Pharmacol 57: 101–107.

Namadurai S, Balasuriya D, Rajappa R, Wiemhöfer M, Stott K, Klingauf J *et al.* (2014). Crystal structure and molecular imaging of the Nav channel β3 subunit indicates a trimeric assembly. J Biol Chem 289: 10797–10811.

Namadurai S, Yereddi NR, Cusdin FS, Huang CL-H, Chirgadze DY, Jackson AP (2015). A new look at sodium channel β subunits. Open Biol 5: 140192.

Nathan AW, Hellestrand KJ, Bexton RS, Banim SO, Spurrell RAJ, Camm AJ (1984). Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate. Am Heart J 107: 222–228.

Ning F, Luo L, Ahmad S, Valli H, Jeevaratnam K, Wang T *et al.* (2016). The RyR2-P2328S mutation downregulates Nav1.5 producing arrhythmic substrate in murine ventricles. Pflügers Arch Eur J Physiol 468: 655–665.

Nitta J, Sunami A, Marumo F, Hiraoka M (1992). States and sites of actions of flecainide on guinea-pig cardiac sodium channels. Eur J Pharmacol 214: 191–197.

Noble D, Noble PJ (2006). Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart 92 (Suppl 4): iv1–iv5.

Nury H, Renterghem CV, Weng Y, Tran A, Baaden M, Dufresne V*et al.* (2011). X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel. Nature 469: 428–431.

Nuyens D, Stengl M, Dugarmaa S, Rossenbacker T, Compernolle V, Rudy Y*et al.* (2001). Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat Med 7: 1021–1027.

Padfield G, Al-Ahmari L, Lieve K, Al-Ahmari T, Roston T, Wilde A *et al.* (2016). Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade. Heart Rhythm 13: 609–613.

Padrini R, Piovan D, Busa M, al-Bunni M, Maiolino P, Ferrari M (1993). Pharmacodynamic variability of flecainide assessed by QRS changes. Clin Pharmacol Ther 53: 59–64.

Papadatos GA, Wallerstein PMR, Head CEG, Ratcliff R, Brady PA, Benndorf K *et al.* (2002). Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proc Natl Acad Sci U S A 99: 6210–6215.

Paul AA, Witchel HJ, Hancox JC (2002). Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol 136: 717–729.

Penniman JR, Kim DC, Salata JJ, Imredy JP (2010). Assessing use-dependent inhibition of the cardiac Na^+ current (INa) in the PatchXpress automated patch clamp. J Pharmacol Toxicol Methods 62: 107–118.

Pott C, Dechering DG, Reinke F, Muszynski A, Zellerhoff S, Bittner A *et al.* (2011). Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature. Europace 13: 897–901.

Pottage A (1983). Clinical profiles of newer class I antiarrhythmic agents-tocainide, mexiletine, encainide, flecainide and lorcainide. Am J Cardiol 52: 24C–31C.

Priori S, Wilde A, Horie M, Cho Y, Behr E, Berul C *et al.* (2013). HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 10: 1932–1963.

Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L, Ronchetti E (2000). The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation 102: 945–947.

Pritchett EL, DaTorre SD, Platt ML, McCarville SE, Hougham AJ (1991). Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. J Am Coll Cardiol 17: 297–303.

Ragsdale DS, McPhee JC, Scheuer T, Catterall WA (1994). Molecular determinants of state-dependent block of Na^+ channels by local anesthetics. Science 265: 1724–1728.

Ramos E, O'Leary ME (2004). State-dependent trapping of flecainide in the cardiac sodium channel. J Physiol 560: 37–49.

Remme CA, Verkerk AO, Nuyens D, van Ginneken ACG, van Brunschot S, Belterman CNW*et al.* (2006). Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD. Circulation 114: 2584–2594.

Rolf S, Haverkamp W, Borggrefe M, Musshoff U, Eckardt L, Mergenthaler J *et al.* (2000). Effects of antiarrhythmic drugs on cloned cardiac voltage-gated potassium channels expressed in Xenopus oocytes. Naunyn Schmiedebergs Arch Pharmacol 362: 22–31.

Roston TM, Vinocur JM, Maginot KR, Mohammed S, Salerno JC, Etheridge SP *et al.* (2015). Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry. Circ Arrhythm Electrophysiol 8: 633–642.

Sabir IN, Li LM, Jones VJ, Goddard CA, Grace AA, Huang CL-H (2008). Criteria for arrhythmogenicity in genetically-modified Langendorff-perfused murine hearts modelling the congenital long QT syndrome type 3 and the Brugada syndrome. Pflugers Arch Eur J Physiol 455: 637–651.

Saint DA (2009). The cardiac persistent sodium current: an appealing therapeutic target? Br J Pharmacol 153: 1133–1142.

Saint DA, Ju YK, Gage PW (1992). A persistent sodium current in rat ventricular myocytes. J Physiol 453: 219–231.

Salvage SC, King JH, Chandrasekharan KH, Jafferji DIG, Guzadhur L, Matthews HR *et al.* (2015). Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts. Acta Physiol 214: 361–375.

Savio-Galimberti E, Knollmann BC (2015). Channel activity of cardiac ryanodine receptors (RyR2) determines potency and efficacy of flecainide and R-propafenone against arrhythmogenic calcium waves in ventricular cardiomyocytes. PLoS One 10 e0131179.

Shimizu W, Antzelevitch C (1999). Cellular and ionic basis for T-wave alternans under long-QT conditions. Circulation 99: 1499–1507.

Shryock JC, Song Y, Rajamani S, Antzelevitch C, Belardinelli L (2013). The arrhythmogenic consequences of increasing late INa in the cardiomyocyte. Cardiovasc Res 99: 600–611.

Sikkel MB, Collins TP, Rowlands C, Shah M, O'Gara P, Williams AJ *et al.* (2013). Flecainide reduces Ca^{2+} spark and wave frequency via inhibition of the sarcolemmal sodium current. Cardiovasc Res 98: 286–296.

Slawsky MT, Castle NA (1994). K^+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes. J Pharmacol Exp Ther 269: 66–74.

Smith G (1985). Flecainide: a new class Ic antidysrhythmic. Drug Intell Clin Pharm 19: 703–707.

Smith GL, MacQuaide N (2015). The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT. Circ Res 116: 1284–1286.

Somani P (1980). Antiarrhythmic effects of flecainide. Clin Pharmacol Ther 27: 464–470.

Somberg JC, Tepper D (1986). Flecainide: a new antiarrhythmic agent. Am Heart J 112: 808–813.

Southan C, Sharman J, Benson H, Faccenda E, Pawson A, Alexander SP *et al.* (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44: D1054–D1068.

Stokoe KS, Balasubramaniam R, Goddard CA, Colledge WH, Grace AA, Huang CL-H (2007a). Effects of flecainide and quinidine on arrhythmogenic properties of $Scn5a^{+/-}$ murine hearts modelling the Brugada syndrome. J Physiol 581: 255–275.

Stokoe KS, Thomas G, Goddard CA, Colledge WH, Grace AA, Huang CL-H (2007b). Effects of flecainide and quinidine on arrhythmogenic properties of $Scn5a^{+}$/Delta murine hearts modelling long QT syndrome 3. J Physiol 578: 69–84.

Tamargo J, Tamargo J, Caballero R, Caballero R, Gómez R, Gómez R *et al.* (2004). Pharmacology of cardiac potassium channels. Cardiovasc Res 62: 9–33.

Tan HL, Kupershmidt S, Zhang R, Stepanovic S, Roden DM, Wilde AAM *et al.* (2002). A calcium sensor in the sodium channel modulates cardiac excitability. Nature 415: 442–447.

Thomas G, Killeen MJ, Grace AA, Huang CL-H (2008). Pharmacological separation of early afterdepolarizations from arrhythmogenic substrate in deltaKPQ Scn5a murine hearts modelling human long QT 3 syndrome. Acta Physiol 192: 505–517.

Ulbricht W (2005). Sodium channel inactivation: molecular determinants and modulation. Physiol Rev 85: 1271–1301.

Viswanathan PC, Balser JR (2004). Inherited sodium channelopathies: a continuum of channel dysfunction. Trends Cardiovasc Med 14: 28–35.

Viswanathan PC, Bezzina CR, George AL, Roden DM, Wilde AA, Balser JR (2001). Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation 104: 1200–1205.

Wang GK, Russell C, Wang SY (2003). State-dependent block of wild-type and inactivation-deficient Na^+ channels by flecainide. J Gen Physiol 122: 365–374.

Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG *et al.* (1995a). Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet 4: 1603–1607.

Wang Z, Fermini B, Nattel S (1995b). Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther 272: 184–196.

Wang ZG, Pelletier LC, Talajic M, Nattel S (1990). Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. Circulation 82: 274–283.

Wangüemert-Pérez F, Ruiz-Hernández PM, Campuzano O, Caballero-Dorta E, Bosch C, Brugada J *et al.* (2014). Flecainide in patient with aggressive catecholaminergic polymorphic ventricular tachycardia due to novel RYR2 mutation. Minerva Cardioangiol 62: 363–366.

Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE *et al.* (2009). Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15: 380–383.

Watanabe H, Van Der Werf C, Roses-Noguer F, Adler A, Sumitomo N, Veltmann C *et al.* (2013). Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 10: 542–547.

Van Der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A *et al.* (2011). Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 57: 2244–2254.

Willis BC, Ponce-Balbuena D, Jalife JJ (2015). Protein assemblies of sodium and inward rectifier potassium channels control cardiac excitability and arrhythmogenesis. Am J Physiol Heart Circ Physiol 308: H1463–H1473.

Windle JR, Geletka RC, Moss AJ, Zareba W, Atkins DL (2001). Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. Ann Noninvasive Electrocardiol 6: 153–158.

Wingo TL, Shah VN, Anderson ME, Lybrand TP, Chazin WJ, Balser JR (2004). An EF-hand in the sodium channel couples intracellular calcium to cardiac excitability. Nat Struct Mol Biol 11: 219–225.

Winkelmann BR, Leinberger H (1987). Life-threatening flecainide toxicity: a pharmacodynamic approach. Ann Intern Med 106: 807–814.

Wolpert C, Echternach C, Veltmann C, Antzelevitch C, Thomas GP, Spehl S *et al*. (2005). Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm 2: 254–260.

Wu J, Zhang Y, Zhang X, Cheng L, Lammers WJ, Grace AA *et al*. (2012). Altered sinoatrial node function and intra-atrial conduction in murine gain-of-function Scn5a^{+}/ΔKPQ hearts suggest an overlap syndrome. AJP Hear Circ Physiol 302: H1510–H1523.

Yarov-Yarovoy V, McPhee JC, Idsvoog D, Pate C, Scheuer T, Catterall WA (2002). Role of amino acid residues in transmembrane segments IS6 and IIS6 of the Na^{+} channel alpha subunit in voltage-dependent gating and drug block. J Biol Chem 277: 35393–35401.

Yu EJ, Ko S-H, Lenkowski PW, Pance A, Patel MK, Jackson AP (2005). Distinct domains of the sodium channel beta3-subunit modulate channel-gating kinetics and subcellular location. Biochem J 392: 519–526.

Zhang X, Ren W, DeCaen P, Yan C, Tao X, Tang L *et al*. (2012). Crystal structure of an orthologue of the NaChBac voltage-gated sodium channel. Nature 486: 130–134.

Zhang Y, Wu J, Jeevaratnam K, King JH, Guzadhur L, Ren X *et al*. (2013). Conduction slowing contributes to spontaneous ventricular arrhythmias in intrinsically active murine RyR2-P2328S hearts. J Cardiovasc Electrophysiol 24: 210–218.